NEW YORK (GenomeWeb News) – Opaldia will distribute DiaGenic’s breast cancer blood test in the UK and will use a research-use-only version of the test in its own studies until the test receives the CE Mark for use in Europe.
 
Opaldia will offer the gene expression test to UK patients under its Breastcare Program. The firm already offers Agendia’s MammaPrint, which is used in disease prognosis, and Agendia's CupPrint, which identifies the origin of metastasized tumors.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.